Bromocriptine

CLINICAL USE

  • Parkinsonism (but not drug-induced extrapyramidal symptoms)
  • Endocrine disorders

    DOSE IN NORMAL RENAL FUNCTION

  • Parkinson’s disease: Week 1: 1–1.25 mg at night —Week 2: 2–2.5 mg at night —Week 3: 2.5 mg twice daily —Week 4: 2.5 mg, 3 times daily —then increasing by 2.5 mg every —3–14 days according to response – usual range 10–40 mg daily
  • Hypogonadism/galactorrhoea, infertility: 1–1.25 mg at night, increased gradually; usual dose 7.5 mg daily in divided doses (maximum 30 mg daily); infertility without hyperprolactinaemia: 2.5 mg twice daily
  • Cyclical benign breast disease and cyclical menstrual disorders: 1–1.25 mg at night increased gradually; usual dose 2.5 mg twice daily
  • Acromegaly: 1–1.25 mg at night increased gradually to 5 mg every 6 hours
  • Prolactinoma: 1–1.25 mg at night increased gradually to 5 mg every 6 hours (maximum 30 mg daily)

    PHARMACOKINETICS

  • Molecular weight                           :750.7 (as mesilate)
  • %Protein binding                           :90–96
  • %Excreted unchanged in urine     : 2.5–5.5
  • Volume of distribution (L/kg)       :1–3
  • half-life – normal/ESRD (hrs)      :8–20/–

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

  • 20 to 50     : Dose as in normal renal function
  • 10 to 20     : Dose as in normal renal function
  • <10           : Dose as in normal renal function

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD                :Not dialysed. Dose as in normal renal function
  • HD                     :Not dialysed. Dose as in normal renal function
  • HDF/high flux   :Unknown dialysability. Dose as in normal renal function
  • CAV/VVHD      :Not dialysed. Dose as in normal renal function

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugsIncreased risk of toxicity with bromocriptine and isometheptene or phenylpropanolamine

    ADMINISTRATION

    Reconstition

    Route

    Oral

    Rate of Administration

    Comments

    Take with food

    OTHER INFORMATION

  • Hypotensive reactions may occur during the first few days of treatment. Tolerance may be reduced by alcoholDigital vasospasm can occur
  • Concomitant administration of macrolide antibiotics may elevate bromocriptine levels.
  • Related News